Amgen's (AMGN.US) new drug in China has been approved for clinical trial again.
1min read On September 4, the latest official announcement on the website of the National Medical Products Administration's Drug Review Center (CDE) showed that a new clinical application of AMG 451, a new drug of Amgen (AMGN.US), was approved for the treatment of nodular prurigo. According to public information, AMG 451 (rocatinlimab) is an in-development new drug that is a fully human anti-OX40 monoclonal antibody, and Amgen has acquired the right to co-develop and commercialize the product through a collaboration worth up to $1.25 billion.The screenshot source: CDE's websiteOX40 (also known as CD134) is a class of important T cell co-stimulatory molecules and is one of the cutting-edge targets in recent new drug development. On the one hand, it can enhance immune activity by regulating the proliferation and survival of effector T cells, and on the other hand, it can inhibit the activity and proliferation of regulatory T cells (Tregs). Therefore, the design of OX40 agonists to stimulate immune reactions aims to enhance T cell effects and enhance immune responses. The development of OX40-targeted antibodies is expected to bring therapeutic effects for various immune diseases.According to the China Drug Clinical Trial Registration and Information Disclosure Platform, Amgen has already launched multiple clinical studies of AMG 451 in China, including atopic dermatitis and asthma. This time, AMG 451 was again approved for clinical trials, indicating that the product is about to explore clinical trials in a new field of nodular prurigo.